---
title: Insurance for MedTech Startups: Liability and Coverage
description: What insurance MedTech startups actually need: product liability, clinical trial, D&O, and professional indemnity coverage under MDR.
authors: Tibor Zechmeister, Felix Lenhard
category: Team Building, Operations & Scaling
primary_keyword: insurance MedTech startup product liability
canonical_url: https://zechmeister-solutions.com/en/blog/insurance-medtech-startups
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Insurance for MedTech Startups: Liability and Coverage

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **MedTech startups need four distinct insurance categories: product liability (legally linked to MDR Article 10(16) financial coverage obligations), clinical investigation insurance (required by MDR Article 62(4)(k) for sponsors), Directors and Officers liability, and professional indemnity. MDR explicitly requires financial coverage proportionate to risk class — the rest is market-driven and investor-driven, but no less essential.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- MDR Article 10(16) requires manufacturers to have measures in place providing sufficient financial coverage for potential liability under Directive 85/374/EEC, proportionate to risk class, device type, and company size.
- MDR Article 62(4)(k) requires clinical investigation sponsors to ensure provisions for compensation of subjects in case of injury, which in most EU member states means mandatory clinical trial insurance.
- Product liability insurance for a Class IIa device startup typically runs EUR 5,000 to EUR 25,000 per year at EUR 1-5M coverage; Class III can be multiples of that.
- Clinical investigation insurance is scoped per study, per subject, and per country — it is not covered by general product liability.
- D&O (Directors and Officers) and professional indemnity are not MDR requirements but are expected by investors, board members, and large hospital customers.
- Getting insurance in place too late is a classic founder mistake — underwriters want to see your QMS, risk file, and clinical plan before they quote, and that takes weeks.

## Why insurance is not optional for MedTech startups

Founders coming from software backgrounds often underestimate how much insurance MedTech requires. A pure SaaS company might get by with basic general liability and call it a day. A MedTech startup placing a device on the EU market has a legal obligation under MDR to carry financial coverage, a practical obligation to carry clinical trial insurance the moment the first patient is enrolled, and a commercial obligation to carry D&O the moment a serious investor shows up.

Tibor has seen startups lose deals because they could not produce a certificate of insurance when a hospital procurement team asked for one. He has also seen founders scramble to buy clinical trial insurance two weeks before enrollment, only to discover underwriters need four to six weeks and a complete Clinical Investigation Plan to quote. Insurance is not a paperwork task you do at the end. It is infrastructure you build alongside your QMS.

The good news: once you understand the four categories and how MDR maps to them, the decisions get simple.

## What MDR actually says about financial coverage

**MDR Article 10(16)** — General obligations of manufacturers — requires that manufacturers have measures in place to provide sufficient financial coverage in respect of their potential liability under Directive 85/374/EEC (the Product Liability Directive), without prejudice to more protective national measures. The coverage must be proportionate to the risk class, type of device, and size of the enterprise.

In plain language: MDR does not prescribe a specific euro amount, and it does not literally require you to buy insurance. It requires you to be able to pay if your device injures someone. In practice, the only realistic way for a startup to demonstrate this is by holding product liability insurance. A notified body reviewing your QMS will expect to see evidence of this during certification, and national competent authorities can check it during market surveillance.

**MDR Article 62(4)(k)** — Conditions for conducting a clinical investigation — requires that provisions are in place to ensure compensation of subjects in the event of injury suffered as a result of participating in a clinical investigation. This is separate from product liability. It covers trial subjects, not end users of a marketed device. Most EU member states implement this through mandatory clinical trial insurance with minimum per-subject and per-study limits set by national law.

**MDR Article 69** — though you will sometimes see it cited for insurance — deals with damages and compensation in the clinical investigation context for sponsors established outside the Union. The core sponsor insurance obligation lives in Article 62. If any specific interpretation here is load-bearing for your compliance strategy, verify with your national competent authority.

**EN ISO 14155:2020+A11:2024** — the Good Clinical Practice standard referenced by MDR — adds practical detail: insurance must cover both the sponsor and the investigators, and coverage terms must be documented in the Clinical Investigation Plan.

## The four categories MedTech startups need

### 1. Product liability insurance

This is the one MDR Article 10(16) is pointing at. It covers bodily injury and property damage caused by your device once it is on the market. Typical coverage for a Class IIa device startup is EUR 1M to EUR 5M per claim. Class IIb and Class III devices need significantly higher limits — EUR 5M to EUR 25M is common, and high-risk implantables can go higher still.

Price range (rough, European market, 2026):
- Class I: EUR 2,000 to EUR 8,000 per year
- Class IIa: EUR 5,000 to EUR 25,000 per year
- Class IIb: EUR 15,000 to EUR 60,000 per year
- Class III: EUR 40,000 to EUR 200,000+ per year

These numbers assume a startup with no revenue yet, one or two products, and a clean claims history. Revenue exposure, geographic scope (adding the US dramatically changes pricing), and claims history shift everything.

### 2. Clinical investigation insurance

Required by MDR Article 62(4)(k) for any clinical investigation under MDR Chapter VI. This is a separate policy, scoped per study, per protocol, per country. It covers injury to trial subjects.

Key design decisions:
- Per-subject limit and aggregate limit (national law sets minimums — Germany, France, and Austria all have different thresholds)
- Geographic scope (every country in your investigation needs to be listed)
- Duration of coverage including follow-up period (for implantables and long-term devices, coverage must extend years beyond the last patient visit)

Price varies wildly. A small first-in-human software investigation might cost EUR 3,000 to EUR 10,000. A multi-center Class III investigation can run EUR 30,000 to EUR 150,000 per year.

### 3. Directors and Officers (D&O) liability

Not an MDR requirement. But the moment you take institutional investment — or add independent board members — D&O becomes expected. It protects directors and officers personally against claims of mismanagement, breach of fiduciary duty, and regulatory action.

For early-stage MedTech, expect EUR 3,000 to EUR 15,000 per year for EUR 1-5M of coverage. Investors frequently require it as a closing condition.

### 4. Professional indemnity / errors and omissions

Covers claims arising from professional services or advice — relevant if your software gives clinical recommendations, if you provide any consulting component, or if you have service-level obligations to hospital customers. Sometimes bundled with product liability, sometimes separate.

Expect EUR 2,000 to EUR 10,000 per year for a software-focused MedTech startup.

## A worked example

A six-person Austrian startup developing a Class IIa diagnostic imaging software (SaMD under MDR Annex VIII Rule 11) is 18 months from CE marking and planning a 60-subject clinical investigation in Austria and Germany to support their Clinical Evaluation Report.

Here is what they put in place:

**Month 1 of Clinical Investigation Plan drafting:** Start insurance broker conversations. The broker needs the draft CIP, intended purpose, risk file summary, QMS scope, and founder CVs.

**Month 3, before submission to ethics committees:** Clinical trial insurance bound. Austrian and German regulators require proof of coverage as part of the investigation application dossier. Cost: EUR 14,000 for the full study period with a three-year follow-up tail.

**Month 4, seed round closes:** D&O policy bound as an investor closing condition. EUR 5,000 per year, EUR 2M limit.

**Month 16, two months before planned CE mark:** Product liability insurance bound. Notified body wants to see it referenced in the QMS and Post-Market Surveillance Plan. Cost: EUR 12,000 per year, EUR 3M limit, EU-only geographic scope.

**Annual refresh:** All policies reviewed in Q1 against updated revenue projections, claims history, and any new indications or markets.

Total annual insurance burn at CE mark: roughly EUR 31,000. This is a real line item in the budget. It is not optional.

## The Subtract to Ship playbook

What you actually need to do, in order:

**Step 1 — Map your four categories.** Write a one-page document listing: product liability (MDR Art. 10(16) driver), clinical trial (MDR Art. 62(4)(k) driver, only if you will run investigations), D&O (investor-driven), professional indemnity (customer contract driver). If a category does not apply yet, note the trigger event that will make it apply.

**Step 2 — Find a broker who knows MedTech.** Generalist commercial brokers will quote you but will not understand Class IIa versus Class IIb pricing differences or the tail-coverage requirements for implantables. Ask for references from other MedTech startups.

**Step 3 — Prepare the underwriting dossier.** Brokers need: intended purpose, classification with justification, QMS scope, risk file summary, clinical evaluation status, revenue projections, founder and key personnel CVs. Assemble this once and reuse it.

**Step 4 — Buy clinical trial insurance before ethics submission.** Not after. Not at the same time. Before — because ethics committees and competent authorities want proof of coverage in the application.

**Step 5 — Buy product liability insurance before notified body stage 2 audit.** Your notified body will look for it as part of QMS review against EN ISO 13485:2016+A11:2021 clause 5 (management responsibility, risk-based thinking).

**Step 6 — Review annually.** Insurance is not set and forget. Every new indication, new market, new product variant changes the risk profile. Your broker should touch base every year, minimum.

## Reality Check

1. Can you point to the MDR article that drives your product liability obligation, and explain what "proportionate to risk class" means for your specific device?
2. Have you mapped each of the four insurance categories to a trigger event (CE mark, first clinical subject, seed close, first enterprise customer)?
3. Do you have a broker who has placed MedTech risks before, or are you using a generalist?
4. Is your clinical trial insurance geographic scope aligned with every country in your Clinical Investigation Plan?
5. Does your product liability cover the geographies where your device will actually be sold — and does it explicitly exclude or include the US?
6. Have you scheduled the insurance review into your annual QMS management review (per ISO 13485 clause 5.6)?
7. If an investor asked for a certificate of insurance tomorrow, could you produce it within 48 hours?

## Frequently Asked Questions

**Does MDR actually require insurance, or just "financial coverage"?**
MDR Article 10(16) requires financial coverage proportionate to risk class, device type, and enterprise size — it does not literally mandate an insurance policy. For a startup, insurance is the only practical way to demonstrate coverage. A cash reserve large enough to self-insure a Class III implantable claim is not a realistic option for most founders.

**When should I buy product liability insurance — before or after CE mark?**
Before. Your notified body expects to see it in place as part of QMS review before issuing the certificate. Underwriters also need weeks of lead time, so start conversations at least two months before you need the policy bound.

**Is clinical trial insurance the same as product liability?**
No. They cover different risks and different populations. Product liability covers injury from a marketed device to end users. Clinical trial insurance covers injury to subjects enrolled in a clinical investigation under MDR Chapter VI. You need both if you are running an investigation before CE mark.

**Do I need D&O insurance if I am still pre-seed?**
Usually not. D&O becomes relevant when you take institutional money, add independent board members, or expand your leadership team significantly. Most seed investors will ask for it as a closing condition.

**What happens if I run a clinical investigation without insurance?**
The investigation application will be rejected by the competent authority and ethics committee. MDR Article 62(4)(k) makes compensation provisions a condition for conducting an investigation. Without proof of coverage, you will not get approval to start.

**How much does the US market add to product liability pricing?**
Typically 3x to 10x. US litigation risk is in a different category than EU. If you are pursuing FDA clearance in parallel, make sure your broker understands this and quotes accordingly.

## Related reading
- [Clinical investigation compensation and insurance](/blog/clinical-investigation-financial-compensation-insurance) — deep dive on MDR Article 62(4)(k) and national implementation.
- [True cost of CE marking](/blog/true-cost-ce-marking-transparent-breakdown) — insurance is a real line item founders usually forget.
- [MedTech startup budget planning](/blog/medtech-startup-budget-planning) — how insurance fits into the full burn model.
- [Sponsor obligations in clinical investigations](/blog/sponsor-obligations-clinical-investigations-mdr) — insurance is one of several sponsor duties under MDR Chapter VI.
- [Burn rate management for MedTech](/blog/burn-rate-management-medtech) — annual insurance costs are a fixed burn item, not a variable one.

## Sources
1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 10(16), Article 62(4)(k), Article 69, Chapter VI.
2. Council Directive 85/374/EEC on liability for defective products, as amended.
3. EN ISO 14155:2020+A11:2024 — Clinical investigation of medical devices for human subjects — Good clinical practice.

---

*This post is part of the [Team Building, Operations & Scaling](https://zechmeister-solutions.com/en/blog/category/team-operations) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*